Cerity Partners LLC Buys 19,370 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cerity Partners LLC lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 322,234 shares of the medical research company's stock after purchasing an additional 19,370 shares during the quarter. Cerity Partners LLC owned 0.18% of IQVIA worth $74,558,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in the business. AdvisorNet Financial Inc increased its stake in IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company's stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. BKM Wealth Management LLC bought a new position in IQVIA in the fourth quarter valued at approximately $32,000. ST Germain D J Co. Inc. bought a new position in IQVIA in the second quarter valued at approximately $33,000. Activest Wealth Management acquired a new stake in IQVIA in the fourth quarter valued at approximately $35,000. Finally, CVA Family Office LLC acquired a new stake in IQVIA in the fourth quarter valued at approximately $43,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Down 1.6 %

IQV stock traded down $3.79 during midday trading on Friday, hitting $234.23. The stock had a trading volume of 892,876 shares, compared to its average volume of 983,311. The firm has a market cap of $42.51 billion, a P/E ratio of 32.13, a price-to-earnings-growth ratio of 2.32 and a beta of 1.50. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The business has a fifty day moving average price of $243.47 and a two-hundred day moving average price of $220.60.

IQVIA (NYSE:IQV - Get Free Report) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to analyst estimates of $3.80 billion. IQVIA had a net margin of 9.06% and a return on equity of 29.32%. IQVIA's revenue for the quarter was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.54 earnings per share. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.11 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, insider Ari Bousbib sold 31,678 shares of the company's stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $241.50, for a total transaction of $241,500.00. Following the transaction, the insider now owns 20,836 shares in the company, valued at approximately $5,031,894. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 over the last quarter. Company insiders own 1.60% of the company's stock.

Analyst Ratings Changes

A number of brokerages have weighed in on IQV. Truist Financial raised their target price on shares of IQVIA from $286.00 to $297.00 and gave the company a "buy" rating in a research report on Tuesday, February 27th. BTIG Research began coverage on shares of IQVIA in a research report on Tuesday, February 13th. They issued a "buy" rating and a $285.00 target price on the stock. StockNews.com upgraded shares of IQVIA from a "hold" rating to a "buy" rating in a research report on Friday, February 16th. Evercore ISI raised their target price on shares of IQVIA from $255.00 to $265.00 and gave the company a "market outperform" rating in a research report on Thursday, February 15th. Finally, UBS Group raised their target price on shares of IQVIA from $240.00 to $300.00 and gave the company a "buy" rating in a research report on Thursday, February 15th. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $256.80.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.